Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis

BACKGROUND: Tolvaptan slows kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD) who are at risk of rapid progression. Given that treatment requires commitment to long-term use, we evaluated the effects of tolvaptan discontinuation on the trajectory of ADPKD...

Descripción completa

Detalles Bibliográficos
Autores principales: Lioudis, Michael, Zhou, Xiaolei, Davenport, Eric, Nunna, Sasikiran, Krasa, Holly B., Oberdhan, Dorothee, Fernandes, Ancilla W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286436/
https://www.ncbi.nlm.nih.gov/pubmed/37349694
http://dx.doi.org/10.1186/s12882-023-03247-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286436/
https://www.ncbi.nlm.nih.gov/pubmed/37349694
http://dx.doi.org/10.1186/s12882-023-03247-6

Ejemplares similares